Prelude Capital Management’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Prelude Capital Management’s Portfolio GRTS Stock Details GRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,169	Closed	-$28.3K	–	1407
2023 Q1	$28.3K	Buy	+10,169	New	+$29.1K	﹤0.01%	1034
2020 Q3	–	Sell	-26,924	Closed	-$179K	–	2469
2020 Q2	$179K	Buy	+26,924	New	+$181K	0.01%	771
2020 Q1	–	Sell	-2,862	Closed	-$26K	–	2146
2019 Q4	$26K	Buy	+2,862	New	+$23.9K	﹤0.01%	1534
2019 Q1	–	Sell	-28,509	Closed	-$440K	–	2275
2018 Q4	$440K	Buy	+28,509	New	+$544K	0.03%	503

Other funds holding GRTS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's GRTS Position: Q2 2023 in Review

Prelude Capital Management sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q2 2023, closing a stake of 10,169 shares — an estimated $28.3K sold.

Prelude Capital Management first reported a position in GRTS in Q4 2018 and held it in 4 quarters. The position peaked at $440K in Q4 2018. 88 funds tracked by Wall St. Rank hold GRTS as of Q2 2023.

Prelude Capital Management reported no remaining Gritstone bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 10,169 Gritstone bio, Inc. Common Stock shares in Q2 2023, an estimated $28.3K.
Prelude Capital Management first reported a position in Gritstone bio, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
Prelude Capital Management's Gritstone bio, Inc. Common Stock position peaked at $440K in Q4 2018.
88 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.